Drug intelligence / Profile preview

ZSP1241

Development stage: Phase 1
Lead developer: Zhongsheng Pharma
Modality: Small Molecules
Administration: Oral

Overview

ZSP1241 is a potent and selective small molecule inhibitor of the c-Met (Hepatocyte Growth Factor Receptor) tyrosine kinase, developed by Guangdong South China Pharmaceutical Group (a subsidiary of Zhongsheng Pharmaceutical). The c-Met signaling pathway is frequently dysregulated in various malignancies, including hepatocellular carcinoma, where it promotes tumor cell proliferation, survival, invasion, and angiogenesis. By specifically targeting and inhibiting the MET receptor, ZSP1241 aims to suppress these oncogenic processes. It is currently undergoing Phase 1 clinical evaluation for the treatment of advanced solid tumors, with a particular focus on patients with hepatocellular carcinoma.

Other names: ZSP 1241ZSP1241ZSP-1241

Targets

FGFR4 (Fibroblast growth factor receptor 4)

Beyond the preview

Go deeper on ZSP1241.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZSP1241.

Explore the full profile